ChAdOx1-HBV

BIOLOGICAL3 trials

Sponsors

Barinthus Biotherapeutics

Conditions

Chronic Hepatitis BHealthyHepatitis B

Phase 1

First in Human Study of ChAdOx1-HBV in Healthy Participants and Participants With Chronic hepB Infection

CompletedNCT04297917

Barinthus BiotherapeuticsHealthy, Hepatitis B

Start: 2019-02-10End: 2022-06-26Updated: 2025-08-12

First-In-Human Study of ChAdOx1-HBV & MVA-HBV Vaccines (VTP-300) for Chronic HBV

CompletedNCT04778904

Barinthus BiotherapeuticsHepatitis B

Start: 2020-12-22End: 2023-02-24Updated: 2024-08-13

Phase 2

Efficacy of VTP-300 in Chronic Hepatitis B Infection

CompletedNCT05343481

Barinthus BiotherapeuticsChronic Hepatitis B

Start: 2022-09-21End: 2026-01-13Updated: 2026-04-30

Related Papers

Population Pharmacokinetics and Exposure–Response Analysis of Serplulimab in Small Cell Lung Cancer Patients

Clinical and Translational Science2025-09-01

HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV.

2023-08-188 citations